Cancer Control最新文献

{"title":"Generative AI - Assisted Adaptive Cancer Therapy.","authors":"Youcef Derbal","doi":"10.1177/10732748251349919","DOIUrl":"10.1177/10732748251349919","url":null,"abstract":"<p><p>Adaptive combination therapy is deemed the most intuitive strategy to thwart therapeutic resistance through dynamic treatment tuning that accounts for cancer evolutionary dynamics. However, higher accuracy and reliability of treatment response predictions would be needed, in addition to the need for clinically feasible models of adaptive combination therapy that consider newly approved therapeutics and the growing multimodal data being available about cancer. Grounded in nonlinear system control theory, this review offers a perspective on exploiting GenAI learning and inferencing capabilities to predict treatment response and recommend treatments in the context of adaptive cancer therapy. Results from nonlinear system identification, control theory and deep learning are integrated within an adaptive cancer control framework to leverage the continuously expanding data about cancer and its treatment towards GenAI-enhanced adaptive therapy. The resulting models and their analysis contribute to a much-needed conceptual clarity about the research and translational pathways that would be needed to realize GenAI-assisted cancer treatments. In particular, they underscore that access to clinical data, deep learning opacity, and clinical validation present critical challenges that require adequate attention to pave the way towards acceptance and integration of GenAI in real-world oncology workflows.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251349919"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12177262/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144327461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Do Nutritional and Inflammatory Indices Predict Response in Geriatric Gastric Cancer Patients Treated With Neoadjuvant FLOT Regimen?","authors":"Aybala Nur Ucgul","doi":"10.1177/10732748251357471","DOIUrl":"10.1177/10732748251357471","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251357471"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144555411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Biological Role of LRPPRC in Human Cancers.","authors":"Jiaxin Tang, Jing Li, Shiyu Qin, Yu Xiao, Jiaxin Liu, Xian Chen, Yunyuan Zhang","doi":"10.1177/10732748251353077","DOIUrl":"10.1177/10732748251353077","url":null,"abstract":"<p><p>The leucine-rich pentatricopeptide repeat-containing (LRPPRC) protein, a member of the pentatricopeptide repeat (PPR) family, is a mitochondria-associated protein that regulates various biological processes, including cell cycle progression and mitochondrial gene translation. LRPPRC has also been identified as an important causative gene in several mitochondrial diseases. N6-methyladenosine (m6A) is the most prevalent and extensive modification of mRNA in eukaryotes, playing a significant role in cellular proliferation, differentiation, and oncogenesis. As an m6A regulator, LRPPRC has been shown to play an important role in the development of various human metabolic diseases and malignant tumors. This review mainly focuses on summarizing the biological roles of LRPPRC in a variety of human malignant tumors, emphasizing the molecular mechanisms LRPPRC is involved in and its potential impact on tumor prognosis.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251353077"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12214333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144530670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Characteristics and Outcomes of Acute Myeloid Leukemia Patients Harboring <i>NPM1/FLT3-ITD/DNMT3A</i> Triple Mutations and the Potential Prognostic Value of <i>GNG4</i>.","authors":"Yujie Niu, Xingchun Luo, Xiaoxiao Yang, Yuancheng Guo, Xiao Tang, Long Zhao, Jinli Jian, Bei Liu","doi":"10.1177/10732748251359836","DOIUrl":"10.1177/10732748251359836","url":null,"abstract":"<p><p>IntroductionNucleophosmin 1 (<i>NPM1</i>), FMS-like tyrosine kinase 3-internal tandem duplication (<i>FLT3-ITD</i>), and de novo methyl transferase 3 A (<i>DNMT3A</i>) triple-mutated acute myeloid leukemia (AML) represents a distinct entity with poor outcomes.MethodsWe explored the gene mutation spectrum and clinical characteristics of 165 AML patients retrospectively, particularly comparing patients with <i>NPM1/FLT3-ITD/DNMT3A</i> triple-mutations and those without.ResultsOur results demonstrated significantly elevated white blood cell counts (<i>P</i> < 0.001), bone marrow blast percentages (<i>P</i> = 0.037), and platelet counts (<i>P</i> = 0.007) in the triple-mutated cohort (6.7%) compared to the non-triple-mutated patients. Furthermore, all triple-mutated cases were classified as the M4/M5 subtype of the French-American-British classification (<i>P</i> = 0.017). Although no significant difference in complete remission rates was observed between the groups after initial treatment, the median overall survival for triple-mutated AML patients was only 4 months. Using the Gene Expression Omnibus (GEO) database and bioinformatics, we compared AML^{<i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut} and AML^{<i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>wt}. A total of 246 AML patients from the GEO dataset were included to evaluate the expression profiles of differentially expressed genes. The guanine nucleotide-binding protein subunit γ 4 (<i>GNG4</i>) was differentially expressed between AML^{<i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut} and AML^{<i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>wt}, which had the most adjacent nodes among hub genes. The prognostic value of <i>GNG4</i> was further validated in AML patient samples through qRT-PCR.ConclusionClinical validation indicated a substantial downregulation of <i>GNG4</i> in AML^{<i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut} compared to AML^{<i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>wt} patients. Thus, <i>GNG4</i> may play a role in the low survival rate of AML^{<i>NPM1</i>mut<i>FLT3-ITD</i>mut<i>DNMT3A</i>mut} patients, offering novel insights into the prognosis, therapeutic targets, and prognostic evaluation of AML.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251359836"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12276431/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Women-Centric Breast Cancer Care in Low- and Middle-Income Countries: Challenges, Solutions, and a Roadmap for Equity.","authors":"Jabed Iqbal","doi":"10.1177/10732748251378804","DOIUrl":"10.1177/10732748251378804","url":null,"abstract":"<p><p>Breast cancer remains a critical public health challenge in low- and middle-income countries (LMICs), where late-stage diagnoses, limited access to care, and fragmented survivorship support exacerbate disparities in outcomes. This manuscript examines the systemic barriers to delivering women-centric breast cancer care in LMICs, including geographic and socioeconomic inequities, underfunded prevention efforts, and gaps in policy implementation. Building on a proposed roadmap for reform, we advocate for culturally adaptive strategies, community co-creation, and investment in scalable care models. By prioritizing women's unique needs and fostering multisectoral collaboration, LMICs can transform breast cancer care from survival-focused to empowerment-driven, even amid resource constraints.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251378804"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12441264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145076292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alleviating the Global Burden of Cancer Through Prevention and Early Detection.","authors":"Iffat Elbarazi, Luai A Ahmed","doi":"10.1177/10732748251378666","DOIUrl":"10.1177/10732748251378666","url":null,"abstract":"<p><p>This editorial introduces the \"Cancer Control\" Special Collection featuring 14 peer-reviewed diverse studies from diverse geographical regions and thematic areas, including screening, HPV vaccination, cancer literacy, genetic and molecular innovations, and culturally tailored interventions. This collection highlights disparities in access, uptake, and awareness across populations emphasizing the urgent need for evidence-based strategies. It calls for integrated approaches in prevention, health education, policy reform, and technological advancements to reduce the global cancer burden, which continues to rise, especially in low- and middle-income countries.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251378666"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12432317/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145055510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coxsackievirus B3 Inhibited Colorectal Cancer by Upregulating miR-214-3P and Promoting Ferroptosis.","authors":"Shuang Zhu, Fangzhou Liu, Suwen Ou, Xin Tang, Zilong Guan, Guodong Sun, Songlin Ran, Jinhua Ye, Yanni Song, Rui Huang","doi":"10.1177/10732748251376088","DOIUrl":"10.1177/10732748251376088","url":null,"abstract":"<p><p>IntroductionColorectal cancer (CRC) is the third most common cancer worldwide and a significant public health threat with far-reaching societal implications. The currently available CRC therapeutic strategies have limitations, thus requiring the development of new strategies. Coxsackievirus B3 (CVB3) exhibits strong oncolytic activity in CRC, although its mechanism of action remains unclear. This study aimed to investigate whether the induction of ferroptosis is a promising treatment strategy for CRC and whether CVB3 could activate ferroptosis during infection.MethodsIn vitro and in vivo experiments were conducted to evaluate whether CVB3 infection activates the ferroptosis pathway by upregulating miR-214-3p to suppress glutathione peroxidase 4 (GPX4) expression. Dual-luciferase assays and rescue experiments were performed to confirm this regulatory mechanism. Clinical CRC tissues and colon cancer xenograft models were used to demonstrate the mediating role of the miR-214-3p/GPX4 axis in the interaction between viral replication and ferroptosis.ResultsCVB3 demonstrated oncolytic virus properties by selectively lysing tumor cells. The in vitro and in vivo experiments confirmed that CVB3 activates the ferroptosis pathway by upregulating miR-214-3p to suppress GPX4 expression, thereby promoting viral replication and tumor regression. Antagonizing miR-214-3p reversed this process.ConclusionmiR-214-3p expression was upregulated during CVB3 infection of CRC tissues and cells, activating the ferroptosis pathway and promoting tumor cell death.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251376088"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12433557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145058422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Prevalence of Financial Worry in a Cohort of Patients with Advanced Colorectal Cancer: A Secondary Observational Cohort Study.","authors":"Hannah Douglass-Molloy, Philip Akude, Aynharan Sinnarajah, Jessica Simon","doi":"10.1177/10732748251384361","DOIUrl":"https://doi.org/10.1177/10732748251384361","url":null,"abstract":"<p><p>IntroductionFinancial hardship during cancer treatment is common in privatised healthcare systems and has been extensively studied in cancer survivorship groups. The experience of financial concerns by people living with advanced, incurable cancer has been less frequently explored. This paper sought to describe the proportion of patients experiencing financial worry longitudinally, in a cohort with advanced colorectal cancer, in a publicly funded healthcare system.MethodsThis secondary analysis of a prospective, observational cohort study 'Palliative Care Early and Systematic (PaCES)' project, analysed data from 131 patients with advanced colorectal cancer, from Alberta's two tertiary cancer centres, treated between January 2018 - December 2020. Rates of self-reported financial concerns were obtained from the Canadian Problem Checklist, completed monthly for 10 months and 3 monthly thereafter.ResultsFifty-seven patients (43%) affirmed at least once that they had worried about their finances in the preceding month. Of those who reported they had \"noˮ financial concerns at enrolment, 41 (35%) subsequently answered \"yesˮ. The proportion of patients experiencing financial worry at any given time point fluctuated but the mean proportion was 18%. Multivariable analysis confirmed younger age (<65) was associated with more financial worry (<i>P</i>-value <0.01).ConclusionFinancial worry is a common and often recurrent concern for patients with advanced colorectal cancer, particularly for younger patients. Serial screening is important to detect persisting or de novo worry.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251384361"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Factors Influencing Immunotherapy Outcomes in Cancer: Sarcopenia and Systemic Inflammation.","authors":"Erkan Topkan, Nilüfer Kılıç Durankuş, Şükran Şenyürek, Ugur Selek","doi":"10.1177/10732748251318390","DOIUrl":"10.1177/10732748251318390","url":null,"abstract":"","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251318390"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11833821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143442515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of Antibiotic Used During Surgery With the Outcome in Stage I-III Gastric Cancer.","authors":"Lijuan Ding, Mengyu Zhou, Jiahui Yin, Xiaoming Zhang, Qianwen Ye, Niansong Qian","doi":"10.1177/10732748251339261","DOIUrl":"https://doi.org/10.1177/10732748251339261","url":null,"abstract":"<p><p><b>Introduction:</b> The use of antibiotic (Abx) is common in gastric cancer (GC) patients undergoing radical resection; however, the prognostic value of the use of these agents in stage I-III patients remains largely unknown.<b>Methods:</b> Data concerning the use of Abx in GC patients during surgery including the cumulative defined daily dose (cDDD) and types of Abx, were collected retrospectively. Differences in clinical features between cDDD subgroups and type subgroups were compared. Overall survival (OS) differences were tested via the Kaplan-Meier method, and risk factors for survival were validated by a Cox proportional hazards model.<b>Results:</b> Of 162 patients enrolled, 81 were assigned to the low-cDDD and 81 to the high-cDDD group. Among them, 19 patients were assigned to ≤2 types and 143 to ≥3 types. The low- and high-cDDD subgroups of patients presented no significant difference in OS (log rank = 2.21, <i>P</i> = 0.137). Patients receiving ≥3 types presented significantly better OS (log rank = 4.58, <i>P</i> = 0.032) than those receiving ≤2 types. The low- and high-cDDD subgroups (log rank = 3.83, <i>P</i> = 0.050), but not the ≤2 and ≥3 type subgroups (log rank<0.01, <i>P</i> = 0.982), presented a significant difference in OS in patients undergoing total gastrectomy. These differences were maintained in patients without total gastrectomy (cDDD: log rank = 7.92, <i>P</i> = 0.005; types: log rank = 6.52, <i>P</i> = 0.011). The use of multiple Abx types was validated as an independent factor for OS (HR = 0.46, 95% CI: 0.24-0.90; <i>P</i> = 0.024).<b>Conclusions:</b> Abx use during surgery in patients with stage I-III GC may potentially correlate with the prognosis. Patients with ≥3 types of Abx were more likely to have good outcomes, particularly in those without total gastrectomy.</p>","PeriodicalId":49093,"journal":{"name":"Cancer Control","volume":"32 ","pages":"10732748251339261"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12038211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144041656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}